Document is current

Any future updates will be listed below

Erhaltung beim Ovarialkarzinom: PARP-Inhibitor mit Bevacizumab kombinieren

Crossref DOI link: https://doi.org/10.1007/s15015-020-2699-1

Published Online: 2020-12-14

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark